StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $159.75 | $160.97 | +0.76% | 0.1M |
| 05-11 | $161.50 | $158.93 | -1.59% | 0.2M |
| 05-12 | $159.70 | $159.47 | -0.14% | 0.2M |
| 05-13 | $158.95 | $160.65 | +1.07% | 0.2M |
| 05-14 | $161.09 | $161.09 | +0.00% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Annual 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $270.71M | $1.04B | $267.56M | $255.47M |
Operating Income | $55.63M | $209.33M | $157.04M | $102.46M |
Net Income | $40.28M | $154.84M | $40.29M | $38.28M |
EPS (Diluted) | $1.25 | $4.75 | $1.24 | $1.17 |
Total Assets | $1.69B | $1.69B | $1.66B | $1.68B |
Total Liabilities | $408.63M | $428.84M | $363.17M | $410.33M |
Cash & Equivalents | $72.87M | $74.57M | $65.09M | $65.43M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 32.13M | 32.06M | 32.38M | 32.46M |